The Latest Breaking News from biotechnology

The biotechnology industry is witnessing remarkable expansion, propelled by notable advances in drug development, an increase in merger and acquisition activities, proliferation of technological innovations, and strong backing from the government. Given this backdrop, quality biotech stocks Acorda Therapeutics (ACOR), Organogenesis Holdings (ORGO), and Equillium (EQ) could be kept an…

The need for innovative healthcare solutions, personalized medicines and treatments, and the use of advanced technologies will propel the biotech industry forward. Amid this backdrop, let’s explore the investment potential of biotech stocks TG Therapeutics (TGTX), Galapagos (GLPG), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR).

Most biotechnology companies have a broad mandate to perform research and development that addresses the largest market possible. It makes logical sense, the largest market should be the most profitable. But Biomarin stands this model on its head, providing drug treatments for highly specialized, mostly small markets that are underserved,…

Thermo Fisher Scientific and the Centre for Cellular and Molecular Platforms (C-CAMP) recently announced a collaborative initiative to establish a Centre of Excellence in Bengaluru. This state-of-the-art facility will serve as a hub for fostering innovation, accelerating breakthroughs in the biotechnology sector and enabling researchers to enhance their expertise and…

The biotechnology industry is experiencing significant growth, fueled by rising technological innovations and government support. Therefore, it could be wise to consider fundamentally strong biotech stocks Genfit (GNFT), Equillium (EQ), and Innoviva (INVA) for 2024. Read more.

The biotech industry's dynamic growth, spurred by government backing and technological advances, addresses rising disease challenges and propels advancements in healthcare. Hence, fundamentally strong biotech stocks Gilead Sciences (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be solid investments for upcoming year gains. Read more….

The biotechnology industry is experiencing significant growth, fueled by recent breakthroughs in drug development, technological innovations, and robust government support. Given this backdrop, promising biotech stocks Shionogi & Co. (SGIOY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics Corporation (UTHR) could be solid buys for 2024 success. Also, these…

A recent study published in Nature describes an AI-driven advancement in biotechnology with implications for medication discovery, disease diagnosis, and environmental monitoring. Read further on Dynamite News:

The biotechnology industry is flourishing due to the recent breakthroughs in drug development, technological advancements, and strong governmental backing. Given this backdrop, promising biotech stocks Organogenesis Holdings (ORGO), Theratechnologies (THTX), and Vertex Pharmaceuticals (VRTX) could be solid buys to supercharge the portfolios. Read on….

A state-of-the-art bio-safety level-3 (BSL-3) laboratory for research on viruses with high potential for life-threatening diseases has begun functioning under Rajiv Gandhi Centre for Biotechnology (RGCB).

In the ever-evolving realm of biotechnology, technological advancements and breakthroughs are propelling significant growth. Hence, fundamentally strong biotech stocks Equillium (EQ), United Therapeutics (UTHR), and Vertex Pharmaceuticals (VRTX) might be solid investments for weekly year-end gains. Read more….